Develops, manufactures and sells prescription medicines for serious diseases, supplying wholesalers, distributors and specialty pharmacies.
10-K for FY2025, filed Feb 11, 2026We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of…View ↗
We compete with other global research-based drug companies, many smaller research companies with more limited therapeutic focus and generic…View ↗
Our products are sold principally to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals…View ↗
Customers buy medicines through wholesalers, distributors and specialty pharmacies; orders are generally filled within a few days and payment terms are typically 30 to 90 days. Alliance and licensing income can include upfront and milestone payments, royalties on partner sales, and payments for product supply.
10-K for FY2025, filed Feb 11, 2026Net product sales represent more than 95% of total revenues for all periods presented. Products are sold principally to wholesalers…View ↗
Wholesalers are initially invoiced at contractual list prices. Payment terms are typically 30 to 90 days based on customary practices in…View ↗
Transaction prices for these arrangements may include fixed upfront amounts as well as variable consideration such as contingent…View ↗
Most out-licensing arrangements consist of a single performance obligation that is satisfied upon execution of the agreement when the…View ↗
Certain out-licensing arrangements may also include contingent performance obligations to supply commercial product to the third party upon…View ↗
Although collaboration arrangements are unique in nature, both parties are active participants in the operating activities and are exposed…View ↗
$48.2B
10-K for FY2025, filed Feb 11, 2026
$48.2B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product sales
Sold outright
10-K for FY2025, filed Feb 11, 2026 |
97%
FY2022: 97%
|
Net product sales, FY2025
$46.8B Sources
|
Sold outright |
|
Alliance revenues
Licensed
|
0.9%
FY2022: 1.6%
|
Alliance revenues, FY2025
$447M Sources
|
Licensed |
|
Other revenues
Licensed
|
2.1%
FY2022: 1.6%
|
Other revenues, FY2025
$992M Sources
|
Licensed |
Sells mainly through wholesalers, distributors and specialty pharmacies, with smaller sales to retailers, hospitals, clinics, government agencies and patients; it has also announced direct-to-patient offerings for several U.S. products.
10-K for FY2025, filed Feb 11, 2026
Yes. It kept 15 cents of every revenue dollar as net income in FY2025 and turned 27 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Jul 30, 2026
Second quarter revenues increased 6% (+5% Ex-FX) to $13.0 billion Growth Portfolio revenues increased 15% (+14% Ex-FX) to $7.6 billion GAAP…View ↗
Flat. Revenue was $48.2B in FY2025, about the same as the $46.4B of FY2021.
Broader treatment technologies
The product platform description expands beyond small-molecule drugs, biologics and CAR-T therapies to include protein degraders, antibody-drug conjugates and radiopharmaceutical therapeutics.
10-K for FY2022, filed Feb 14, 2023 10-K for FY2025, filed Feb 11, 2026Our pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called…View ↗
Our differentiated research platforms support long-term growth across therapeutic areas. Our platforms are comprised of…View ↗
Loading...